Long-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed or currently untreated recurrent focal-onset seizures: Results from the open-label extension phase of FREEDOM (Study 342)
Patients with untreated FOS (with or without FBTCS) are able to maintain seizure freedom for up to 52 weeks with perampanel monotherapy at a dose of 4-8 mg/day. The tolerability profile was manageable, and the safety profile was consistent with previous findings.
Authors
- Risa Matsunaga (ORCID: https://orcid.org/0000-0003-2698-8849)
- Taku Ochiai (ORCID: https://orcid.org/0000-0003-0127-1665)
- Takamichi Yamamoto (ORCID: https://orcid.org/0000-0003-4883-1551)
- Dong Jin Shin (ORCID: https://orcid.org/0000-0002-4390-2843)
- Hidetaka Hiramatsu
- Hirotomo Ninomiya (ORCID: https://orcid.org/0000-0001-6718-130X)
- Yuichi Kubota (ORCID: https://orcid.org/0000-0002-6487-2065)
- Dong Wook Kim (ORCID: https://orcid.org/0000-0003-4484-0602)
- Ji Hyun Kim (ORCID: https://orcid.org/0000-0003-3411-5714)
- Sung Chul Lim (ORCID: https://orcid.org/0000-0002-2030-6299)
- Won Chul Shin
- Koji Iida (ORCID: https://orcid.org/0000-0002-6234-1236)
Institutions
- Hiroshima University (JP)
- Korea University Medical Center (KR)
- Gachon University Gil Medical Center (KR)
- Seirei Mikatabara General Hospital (JP)
- Konkuk University Medical Center (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Itami City Hospital (JP)
- Kyung Hee University Hospital at Gangdong (KR)
- Seirei Social Welfare Community (JP)
- Eisai (Japan) (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Epilepsy Research
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1016/j.eplepsyres.2024.107494
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77